Dong Sung Bio Pharm.Co.,Ltd. (002210-KS) Stock Split, History Data
Working capital analysis
In terms of working capital, Dong Sung Bio Pharm.Co.,Ltd. maintains a healthy position.
The total current assets of the company are valued at $60814859641.
This represents a growth rate of 11.814% compared to the previous year.
Breaking down the current assets, the cash and investments are worth $6435381432, exhibiting a growth rate of 57.199% year-on-year.
The receivables, another significant portion of the current assets, are valued at $31290911706.
The year-on-year growth rate for receivables is -11.512%.
The inventory, which forms a critical part of the assets, is valued at $19477061282.
This represents a healthy year-on-year growth of 30.422%
On the liabilities side, the company's current liabilities total $44843854847.
This reflects a growth rate of -5.733% over the previous year, indicating the company's financial obligations are well under control.
2023
2022
2021
2020
2019
2018
Cash and investments
6435.38
4093.78
3140.16
14352.11
4278.40
2210.92
Receavebles
31290.91
35361.58
29324.48
27803.01
33260.59
38202.11
Inventory
19477.06
14933.83
15519.08
20281.73
23283.52
17359.88
Other
3611.51
0.00
0.00
0.00
0.00
0.00
Total Current Assets
60814.86
54389.19
49986.32
71507.49
79397.72
87789.49
Acc Payable
11261.11
8851.98
6858.79
9728.63
9978.18
10187.41
Short Term Debt
24732.54
29273.96
19713.99
14046.30
15852.58
20309.79
Other Current Liab
8850.20
9183.68
3729.51
4560.32
3600.90
16172.82
Current Liabilities
44843.85
47571.20
37589.21
47833.13
40549.56
47139.17
Capital Structure
When examining the capital structure of Dong Sung Bio Pharm.Co.,Ltd., it is clear that the company manages a robust portfolio.
The value of their total assets clocks in at $114973284037.
When juxtaposed with the previous year, this marks a growth rate of 6.751%, showcasing the company's ability to steadily grow its asset base.
Turning to liabilities, the company has total liabilities amounting to $75170970298.
Compared to the prior year, this reflects a growth rate of 15.839%.
The long-term debt forms a sizable part of these liabilities, coming in at $18522411316.
Over the last year, the long-term debt has grown by 138.633%.
On the asset side, the cash and equivalent reserves are worth $6435381432.
The year-on-year growth of these reserves is 57.199%.
The company's common stock, another important asset, holds a value of $26100970000, growing at a rate of 0.000% from the previous year.
Finally, the company's retained earnings stand at $-3006949420, marking a growth rate of -360.777% year-over-year.
These earnings represent the profits that Dong Sung Bio Pharm.Co.,Ltd. has chosen to reinvest in the business rather than distribute as dividends.
Total Assets
$114,973.28
Total liabilities
$75,170,970,298.00
Long term debt
$18,522.41
Cash and eqv
$6,435,381,432.00
Goodwill
$0.00
Retained earnings
-$3,006,949,420.00
Common stock
$21,128.17
Enterprise Value
$6.10
Historical dividend key summary
Dong Sung Bio Pharm.Co.,Ltd.'s dividend per share is $30, showing the earnings shared with shareholders per share. It has grown by 0.000% this year, suggesting that the company is generating increased income for shareholders and expecting future earnings growth.
Years
Q1
Q2
Q3
Q4
Total
2013
0.000
0.000
0.000
30.000
30.000
2012
0.000
0.000
0.000
30.000
30.000
2011
0.000
0.000
0.000
30.000
30.000
2010
0.000
0.000
0.000
30.000
30.000
2009
0.000
0.000
0.000
30.000
30.000
2008
0.000
0.000
0.000
30.000
30.000
2007
0.000
0.000
0.000
30.000
30.000
2006
0.000
0.000
0.000
40.000
40.000
2005
0.000
0.000
0.000
30.000
30.000
2004
0.000
0.000
0.000
30.000
30.000
2003
0.000
0.000
0.000
30.000
30.000
2002
0.000
0.000
0.000
30.000
30.000
2001
30.000
0.000
0.000
0.000
30.000
2000
30.000
0.000
0.000
0.000
30.000
Net earnings per share (EPS)
Dong Sung Bio Pharm.Co.,Ltd. has an EPS of $-90.70, which signifies the profit allocated per share of common stock. With a growth rate of 2.115% this year, it indicates the company's increasing profitability and potential for share value growth. This trend signals robust financial performance and future potential.
Years
Q1
Q2
Q3
Q4
Total
2023
33.74
-35.55
-1.95
-86.94
-90.70
2022
-62
-63
60
-27.66
-92.66
2021
-30
-5
-22
-94.51
-151.51
2020
-216.36
2
-107
-277.85
-599.21
2019
-70
-101
11
-201.86
-361.86
2018
-27
55.47
-567
280.31
-258.22
2017
13
10.87
27
-52.26
-1.39
2016
8
-64.39
-34
6.96
-83.43
2015
50
13.62
-28.88
-10.47
24.27
2014
12
8
7.36
-621.12
-593.76
2013
41
-5
-21.4
-121.6
-107.00
2012
87
86
-1
-12.5
159.50
2011
37
54
22
-
113.00
2010
-7
-13
3
-503.53
-520.53
2009
32
11
10
-21.49
31.51
2008
239.4
81.4
-28
-91.14
201.66
2007
43.28
185.6
10.43
-84.31
155.00
Brief information
Dong Sung Bio Pharm.Co.,Ltd. (002210.KS) stock split history
Understanding the historical stock splits of Dong Sung Bio Pharm.Co.,Ltd. (002210.KS) provides insights into its past financial decisions and investor sentiment. A stock split occurs when a company increases its share count by dividing its existing shares. The most recent split took place on December 22, 2008 with a ratio of 5:1. Throughout its history, the company has undergone 1 stock splits. Below, we delve deeper into this history, highlighting past financial strategies.
